Next Article in Journal
E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma
Previous Article in Journal
Preoperative assessment of skin tumor thickness and structure using 14-MHz ultrasound
Medicina is published by MDPI from Volume 54 Issue 1 (2018). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Lithuanian Medical Association, Lithuanian University of Health Sciences, and Vilnius University.
Open AccessArticle

VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms

1
Department of Hematology and Malignant Diseases of Hematopoietic System, Faculty of Medicine, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland
2
Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland
3
Department of Neurological and Neurosurgical Nursing, Faculty of Health Sciences, Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland
*
Author to whom correspondence should be addressed.
Medicina 2017, 53(1), 34-39; https://doi.org/10.1016/j.medici.2017.01.004
Received: 5 May 2015 / Revised: 13 December 2016 / Accepted: 9 January 2017 / Published: 2 February 2017
Background and objective: Data from the literature indicate the relationship between the bone marrow microvessel density and the blood parameters of angiogenesis. The aim of this study was to evaluate selected parameters of angiogenesis (VEGF-A, sVEGFR-1, and sVEGFR- 2) and their correlations with white blood cells, platelets, and red blood cells.Materials and methods: The study included 72 patients (mean age, 61.84 years) with myeloproliferative neoplasms (MPNs): essential thrombocythemia (ET) (n = 46), polycythemia vera (PV) (n = 19), and primary myelofibrosis (PMF) (n = 7). Serum VEGF-A, sVEGFR-1, and sVEGFR- 2 were determined using the ELISA assay.Results: We observed a significantly higher level of VEGF-A and reduced concentrations of sVEGFR-1 and sVEGFR-2 in the whole group of patients with MPNs as compared to controls. Detailed analysis confirmed significantly higher level of VEGF-A and lower concentration of sVEGFR-2 in each subgroups of MPNs patients. However, sVEGFR-1 concentrations were significantly lower only in PV and ET patients.Conclusions: The study showed an increased level of VEGF-A, which may indicate the intensity of neoangiogenesis in the bone marrow. Decreased sVEGFR-1 and sVEGFR-2 in the blood of patients with MPNs may reflect consumption of these soluble receptors. View Full-Text
Keywords: BCR-ABL-negative; myeloproliferative neoplasm; VEGF-A; sVEGFR-1; sVEGFR-2 BCR-ABL-negative; myeloproliferative neoplasm; VEGF-A; sVEGFR-1; sVEGFR-2
MDPI and ACS Style

Gadomska, G.; Stankowska, K.; Boinska, J.; Ślusarz, R.; Tylicka, M.; Michalska, M.; Jachalska, A.; Rość, D. VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms. Medicina 2017, 53, 34-39.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Back to TopTop